The Efficacy and Safety of Pulp Regeneration Induced by SHED Mixed With Hyaluronic Acid Polymerization

Sponsor
Fifth Affiliated Hospital of Guangzhou Medical University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05728346
Collaborator
(none)
30
1
39

Study Details

Study Description

Brief Summary

Dental pulp necrosis is one of the most common pathological conditions that results in tooth loss. However, regeneration of functional dental pulp has proved difficult. Therefore, the investigators conduct a single-arm study to evaluate the efficacy and safety of pulp regeneration induced by SHED mixed with hyaluronic acid polymerization in patients with pulp necrosis of permanent teeth.

Condition or Disease Intervention/Treatment Phase
  • Drug: Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers
N/A

Detailed Description

This study is a single-center, prospective, single-arm study to evaluate the efficacy and safety of pulp regeneration induced by SHED mixed with hyaluronic acid polymerization in patients with pulp necrosis of permanent teeth. This study plans to include 30 subjects from the Department of Stomatology of the Fifth Affiliated Hospital of Guangzhou Medical University. All participants in this study will receive stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers after the preparation and disinfection of the root canal of the affected teeth. All participants will undergo screening and baseline visits. After surgery, the participants will be followed up for 2 years.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Single-arm Clinical Trial Evaluating the Efficacy and Safety of Pulp Regeneration Induced by SHED Mixed With Hyaluronic Acid Polymerization in Patients With Pulp Necrosis of Permanent Teeth
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jun 30, 2026
Anticipated Study Completion Date :
Sep 30, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: single-arm

Drug: Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers
stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers

Outcome Measures

Primary Outcome Measures

  1. Assessment of pulp vitality [1、3、6、12、18、24 months]

    Change in pulpal vitality will be assessed through pulpal response to sensitivity tests (cold, hot and electrical test) in affected tooth.

Secondary Outcome Measures

  1. Blood flow in the root of tooth [1、3、6、12、18、24 months]

    Detection rate of blood flow in the root canal of the affected tooth by laser doppler flowmetry.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients aged 18 to 45 years

  • Patients with pulp necrosis of a single canal permanent tooth due to trauma or caries

  • Patients who have signed informed consent

Exclusion Criteria:
  • Patients with pulp necrosis caused by severe trauma to the tooth, such as crown root fracture, tooth root fracture, tooth displacement, etc

  • Patients with calcification of the apical foramen at the root of the tooth

  • History of hereditary disorders of abnormal tooth development

  • Dental occlusal trauma, bruxism, malocclusion

  • Bad oral habits (sticking out the tongue, biting lips, biting nails, sucking fingers, etc.)

  • Presence of uncontrollable pathological processes in the oral cavity (presence of acute advanced diseases in the oral cavity)

  • Malnutrition (serum albumin concentration<2 g/dl)

  • Patients with history of other systemic, communicable or hereditary diseases have been diagnosed

  • Pregnant, nursing, planning to become pregnant

  • The investigators determined that the patient was not suitable for the study

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Fifth Affiliated Hospital of Guangzhou Medical University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xueli Mao, Chief physician, Fifth Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov Identifier:
NCT05728346
Other Study ID Numbers:
  • Xueli Mao
First Posted:
Feb 15, 2023
Last Update Posted:
Feb 15, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xueli Mao, Chief physician, Fifth Affiliated Hospital of Guangzhou Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2023